Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...
Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...
Genzyme has won a crucial vote by FDA advisers in favor of its single injection form of Synvisc, a therapy that eases knee pain by providing a cushion between joints. The five-member expert panel ...
About 27 million Americans suffer from osteoarthritis -- a condition that causes joint fluid to thin out, resulting in bone-on-bone pain. Surgery is invasive and requires a long recovery. Now, a ...
To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...
Genzyme Corp. is challenging a decision by the Centers for Medicare and Medicaid Services to create a single reimbursement code for osteoarthritis treatments that would drop the reimbuirsement rate ...
The U.S. Food and Drug Administration’s Orthopedic and Rehabilitation Devices Advisory Committee has recommended a Genzyme Corp. osteoarthritis pain reliever for approval. Genzyme, which has ...
CHICAGO (AP) _ Government-approved treatments for knee arthritis in which the joint is injected with fluid often made from rooster combs offer little if any relief, researchers say. Doctors should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results